Cover Image
Market Research Report

Inflammatory Bowel Disease (IBD) Deals Analytics Report, 2010-2019

Published by GervanoRA Data Services LLP Product code 832999
Published Content info 43 Pages
Delivery time: 1-2 business days
Price
Back to Top
Inflammatory Bowel Disease (IBD) Deals Analytics Report, 2010-2019
Published: April 30, 2019 Content info: 43 Pages
Description

GervanoRA's Inflammatory Bowel Disease (IBD) Deals Activity Report, 2010-2019 has analyzed and provided an understanding of the overall competition in partnering landscape in the disease area that has occurred from the year 2010.

GervanoRA has analyzed more than 170 drug candidates in the current development pipeline. Hence, a number of emerging and clinical-stage companies are embarking with collaborations or partnerships with different pharma companies to aid in the development process of their respective drug candidates. In the light of rocketing competition, not only companies, but also universities, institutes and research centers are getting actively involved in the advancements of new medicines for the treatment of the disease.

The report through its meticulous analysis on global therapeutic landscape of IBD deals assists companies in taking future partnering decisions based on competitor's R&D activities; current trends in partnering landscape in order to avoid or mitigate competitive market risks.

For a proper understanding, GervanoRA has segmented the report into sections based on:

  • Analytics based on deal type,
  • Analytics based on deal by value,
  • Analytics based on geography
  • Analytics based on deal maker
  • Year-by-year analytics

The report also includes case studies provided for the deals that were prominent and unique among all the deals.

Table of Contents
Product Code: GERPD005

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. METHODOLOGY
  • 1.3. OTHER AVAILABLE DEALS ANALYSIS REPORTS
  • 1.4. ABOUT US: GERVANORA DATA SERVICES

2. EXECUTIVE SUMMARY

3. ANALYTICS BY DEAL TYPE

  • 3.1. INFLAMMATORY BOWEL DISEASE THERAPY AREA AGREEMENTS
  • 3.2. INFLAMMATORY BOWEL DISEASE THERAPY AREA COLLABORATIONS
  • 3.3. INFLAMMATORY BOWEL DISEASE THERAPY AREA MERGERS & ACQUISITIONS
  • 3.4. INFLAMMATORY BOWEL DISEASE THERAPY AREA FINANCING- GRANT AND FUNDING DEALS
  • 3.5. INFLAMMATOY BOWEL DISEASE THERAPY AREA LICENSING DEALS
  • 3.6. INFLAMMATORY BOWEL DISEASE THERAPY AREA ALLIANCE DEALS
  • 3.7. INFLAMMATORY BOWEL DISEASE THERAPY AREA TERMINATION DEALS

4. ANALYTICS BY DEAL VALUE AND GEOGRAPHY

5. ANALYTICS BY ACTIVE PLAYERS

6. ANALYTICS BY ANNUAL FREQUENCY

7. CASE STUDIES- TOP FIVE PROMINENT DEALS

DEAL 1: CELGENE TO ACQUIRE RECEPTOS, ADVANCING LEADERSHIP IN IMMUNE-INFLAMMATORY DISEASES

DEAL 2: GALAPAGOS AND GILEAD ANNOUNCE GLOBAL PARTNERSHIP TO DEVELOP FILGOTINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND OTHER INFLAMMATORY DISEASES

DEAL 3: NOVARTIS TO ACQUIRE IFM TRE TO DEVELOP FIRST-IN-CLASS NLRP3 ANTAGONIST PORTFOLIO TARGETING INNATE IMMUNE SYSTEM

DEAL 04: ASTRAZENECA AND ORCA PHARMACEUTICALS ANNOUNCE RESEARCH COLLABORATION TO IDENTIFY BEST-IN-CLASS RORĪ“ INHIBITORS TO TREAT AUTO-IMMUNE DISEASES

DEAL 05: BIOMX LICENSES NOVEL BACTERIAL TARGETS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

8. ABBREVIATIONS

LIST OF TABLES

  • TABLE 01: MAJOR AGREEMENTS IN THE IBD AREA
  • TABLE 02: MAJOR COLLABORATIONS IN THE IBD AREA
  • TABLE 03: MAJOR MERGERS AND ACQUISITIONS IN THE IBD THERAPY AREA
  • TABLE 04: MAJOR FINANCING DEALS- GRANTS AND FUNDING IN THE IBD AREA
  • TABLE 05: MAJOR LICENSING DEALS IN THE IBD AREA
  • TABLE 06: MAJOR TERMINATION DEALS IN THE IBD AREA
  • TABLE 07: TOP 10 MAJOR DEALS IN THE IBD AREA RANKED BY DEAL AMOUNT

LIST OF FIGURES

  • FIGURE 01: IBD DEALS, BY DEAL TYPE
  • FIGURE 02: MAJOR ACQUISITIONS IN IBD AREA
  • FIGURE 03: IBD DEAL AMOUNT SHARE BY DEAL TYPE
  • FIGURE 04: IBD DEALS SCENARIO, YEAR V/S DEAL AMOUNT
  • FIGURE 05: IBD DEALS SCENARIO, GEOGRAPHICAL REPRESENTATION
  • FIGURE 06: SOME ACTIVE DEAL MAKERS IN IBD SPACE
  • FIGURE 07: NUMBER OF IBD DEALS, YEAR BY YEAR REPRESENTATION
Back to Top